A single arm and single center open clinical study of PD-1 antibody SHR-1210 in the microsatellite highly unstable (MSI-H) advanced solid tumor
Latest Information Update: 29 Sep 2020
At a glance
- Drugs Camrelizumab (Primary)
- Indications Bladder cancer; Cholangiocarcinoma; Colon cancer; Colorectal cancer; Endometrial cancer; Leiomyosarcoma; Liver cancer; Rectal cancer; Solid tumours; Ureteral neoplasms
- Focus Therapeutic Use
- 28 Sep 2020 Results (n=12) evaluating the efficacy and safety of camrelizumab in advanced or metastatic solid tumour, published in the Journal of Cancer Research and Clinical Oncology
- 31 May 2020 Results (n=12) assessing efficacy and safety of Camrelizumab in advanced or metastatic solid tumor patients, presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 06 Nov 2017 New trial record